seribantumab
mAbexperimental
Seribantumab is a monoclonal antibody designed for the treatment of cancer. It binds to extracellular domain of HER3 blocking NRG1 binding and thereby preventing the activation of the receptor. — Wikipedia
Clinical trial activity
14 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
8
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT00734305)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 2
- Bile Duct Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Ovarian Epithelial · Phase 2
- Cholangiocarcinoma · Phase 2
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Gallbladder Neoplasms · Phase 2
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 2
- Kidney Neoplasms · Phase 2
- Lung Neoplasms · Phase 2
- Neoplasms · Phase 2
- Neuregulin-1 · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Sarcoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 2
- Uterine Neoplasms · Phase 2
Mechanism of action
- Receptor tyrosine-protein kinase erbB-3ANTAGONIST
ERBB3 antagonist
Blocks ligand-dependent activation (phosphorylation) of ErbB3.
ERBB3 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545071 ↗
- WikipediaSeribantumab ↗
- ChEMBLCHEMBL2109402 ↗
Also known as
- mm-121
- mm-121
- mm-121
- sar256212
- sar-256212
- seribantumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04790695 | Phase 2 | Mar 21, 2021 | University of Ottawa |
| NCT04383210 | Phase 2 | Jun 30, 2020 | Elevation Pharmaceuticals, Inc. |
| NCT03241810 | Phase 2 | Aug 15, 2017 | Merrimack Pharmaceuticals |
| NCT02538627 | Phase 1 | Aug 1, 2015 | Merrimack Pharmaceuticals |
| NCT02387216 | Phase 2 | Feb 1, 2015 | Merrimack Pharmaceuticals |
| NCT01436565 | Phase 1 | Nov 1, 2011 | Merrimack Pharmaceuticals, Sanofi |
| NCT01447706 | Phase 2 | Oct 1, 2011 | Merrimack Pharmaceuticals, Sanofi |
| NCT01447225 | Phase 1 | Oct 1, 2011 | Merrimack Pharmaceuticals, Sanofi |
| NCT01451632 | Phase 1 | Oct 1, 2011 | Merrimack Pharmaceuticals, Sanofi |
| NCT01421472 | Phase 2 | Aug 1, 2011 | Merrimack Pharmaceuticals, Sanofi |
| NCT01209195 | Phase 1 | Oct 1, 2010 | Merrimack Pharmaceuticals, Sanofi |
| NCT01151046 | Phase 2 | Jun 1, 2010 | Merrimack Pharmaceuticals |
| NCT00994123 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2010 | Merrimack Pharmaceuticals |
| NCT00734305 | Phase 1 | Jul 1, 2008 | Harvard University, Merrimack Pharmaceuticals, Sanofi, Temple University, Vanderbilt University |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merrimack Pharmaceuticals | For profit | 12 | 11 | 2 | 2008 |
| Sanofi | For profit | 7 | 1 | 2 | 2008 |
| Elevation Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2020 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Ottawa | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 2008 |
7 organizations
Page 1 / 1